This article was originally published in Start Up
Endologix is using creative financing to develop a one-piece AAA device.
You may also be interested in...
Endologix needed cash, Radiance Medical needed a new market. Each found what it needed in a merger which will give Endologix the resources to develop its AAA graft line while helping Radiance segue out of a coronary brachytherapy market all but decimated by drug-eluting stents.
The first generation less-invasive devices for abdominal aortic aneurysm (AAA) surgery haven't yet been approved and the next generation is already here.
Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.